← All trials
NCT05513950
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 15, 2022
- Primary completion
- Jun 30, 2023
- Completion date
- Jun 30, 2023
- First posted
- Aug 24, 2022
- Last posted
- Aug 24, 2022
- Enrollment
- 24
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ChiesiLead sponsor
- Royal Liverpool & Broadgreen University Hospitals NHS TrutsOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.